N@N

Market Maker Surveillance Report. SHZ, HAUP, PWAV, GCFB, AEN, XOMA, Winning Stocks With Lowest Price Friction For Tuesday, Jan

^{Published on 2011-01-04 17:50:31 - WOPRAI}
 

January 4, 2011 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 2564 companies with "abnormal" market making, 1865 companies with positive Friction Factors and 3401 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. CHINA SHEN ZHOU MINING & RES (AMEX:SHZ), HAUPPAUGE DIGITAL INC (NASDAQ:HAUP), POWERWAVE TECHNOLOGIES INC (NASDAQ:PWAV), GRANITE CITY FOOD & BREWERY (NASDAQ:GCFB), ADEONA PHARMACEUTICALS INC (AMEX:AEN), XOMA LTD (NASDAQ:XOMA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     SHZ        $1.580       19.04%       12,164,118      47.32%       11,258,846      43.80%       905,272         5,730   
     HAUP       $0.370       16.82%       878,087         53.46%       750,796         45.71%       127,291         3,440   
     PWAV       $0.450       17.44%       3,244,319       55.24%       2,626,159       44.71%       618,160         13,737  
     GCFB       $1.150       40.35%       148,101         55.62%       110,368         41.45%       37,733          328     
     AEN        $0.450       33.33%       1,162,366       62.67%       642,803         34.66%       519,563         11,546  
     XOMA       $2.070       39.06%       26,087,471      53.53%       22,557,962      46.29%       3,529,509       17,051  

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows XOMA with a dollar gain Tuesday of $2.07000 and a Friction Factor of 17,051 shares. That means that it only took 17,051 more shares of buying than selling to move XOMA higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

CHINA SHEN ZHOU MINING & RES (AMEX:SHZ) - China Shen Zhou Mining & Resources, Inc., through its subsidiaries, engages in exploring, developing, mining, processing, and distributing fluorite ore, zinc, copper, lead, and other nonferrous metals. It owns two properties under production, including Sumochaganaobao fluorite mine in Siziwangqi of Inner Mongolia autonomous region and Qingxing copper mine in Wulatehouqi of Inner Mongolia autonomous region; and owns one property under development, including Keyinbulake copper-zinc multi-metal mine in Aletai of Xinjiang Uygur autonomous region in the People's Republic of China. The company is based in Beijing, the People's Republic of China.

HAUPPAUGE DIGITAL INC (NASDAQ:HAUP) - Hauppauge Digital Inc., through its subsidiaries, engages in the design, development, manufacture, and marketing of analog and digital television (TV) tuner products for the personal computer (PC) market. The companys analog, digital, and other types of TV tuners allow PC users to watch television on a PC screen in a resizable window; enable the recording of TV shows to a PCs hard disk; digital video editing; video conferencing; and the display of digital media stored on a computer to a TV set via a home network. It also provides PCTV products, which allow Windows or Macintosh users to view television programming on their computers. In addition, the company offers other non-TV tuner products, including MediaMVP, a digital media device that enables a user to watch and listen to PC-based videos, music, and pictures on a TV set through a home network; ImpactVCB Video Capture Board, a PCI board for high performance access to digitized video; and Wing software, which enable the user to record TV shows on a personal computer for playback on the Sony Playstation Portable, Apple iPod, and other portable video players. Further, it provides WinTV-CI common interface module that allows the user to watch popular pay TV channels, such as movies and sporting events; and Xfones wireless headphones for PCs and Macs. Hauppauge Digital Inc. sells its products primarily through retailers, PC manufacturers, and distributors in the United States, Europe, and Asia. The company was founded in 1994 and is headquartered in Hauppauge, New York.

POWERWAVE TECHNOLOGIES INC (NASDAQ:PWAV) - Powerwave Technologies, Inc. engages in the design, manufacture, marketing, and sale of wireless solutions for wireless communications networks worldwide. It offers antennas, boosters, combiners, cabinets, shelters, filters, radio frequency power amplifiers, remote radio head transceivers, repeaters, tower-mounted amplifiers, and advanced coverage solutions for use in frequency bands, including cellular, PCS, 3G, and 4G wireless communications networks. Powerwave Technologies sells its products through its direct sales force, independent sales representatives, and resellers to wireless original equipment manufacturers and individual wireless network operators. It was formerly known as Milcom International, Inc. and changed its name to Powerwave Technologies, Inc. in June 1996. The company was founded in 1985 and is based in Santa Ana, California.

GRANITE CITY FOOD & BREWERY (NASDAQ:GCFB) - Granite City Food & Brewery Ltd. engages in the development and operation of a chain of casual dining restaurants in the United States. The companys restaurants also feature on-premises breweries that offer five styles of beer, as well as specialty or seasonal beers. As of March 18, 2010, it operated 26 restaurants in 11 Midwestern states under the name of Granite City Food & Brewery. The company was founded in 1997 and is headquartered in Minneapolis, Minnesota.

ADEONA PHARMACEUTICALS INC (AMEX:AEN) - Adeona Pharmaceuticals, Inc. operates as a pharmaceutical company that develops medicines for central nervous systems and autoimmune diseases. It primarily focuses to in-license clinical-stage drug candidates that have already demonstrated a certain level of clinical efficacy and develop them further to either commercialization or development collaboration. The company is developing various clinical-stage drug candidates that include Trimesta, an investigational oral drug for the treatment of relapsing remitting multiple sclerosis; Zinthionein, an oral, gastro-retentive, and sustained-release medical food candidate for the dietary management of Alzheimers disease and mild cognitive impairment; and Effirma, a centrally-acting investigational oral drug for the treatment of fibromyalgia syndrome. It is also developing dnaJP1, an investigational oral drug for the treatment of rheumatoid arthritis; and CD4 Inhibitor 802-2, an investigational drug for the prevention of severe graft-versus-host disease. In addition, the company engages in commercializing serum-based diagnostic tests, including the CopperProof Panel to assist physicians in identifying patients with zinc deficiency and patients at risk of chronic copper toxicity due to impaired serum copper binding. Further, it involves in the manufacture, testing, and clinical development of tetrathiomolybate for Alzheimers, Parkinsons, and Huntingtons diseases. Adeona Pharmaceuticals, Inc. has a partnership with Meda AB, to develop flupirtine for the treatment of fibromyalgia syndrome. The company was founded in 2001 and is headquartered in Ann Arbor, Michigan.

XOMA LTD (NASDAQ:XOMA) - XOMA Ltd., incorporated in 1981, is a biopharmaceutical company in the field of therapeutic antibody discovery and development. The Company has a royalty interest in one approved therapeutic antibody, RAPTIVA, which is marketed in the United States, Europe and elsewhere, for the treatment of moderate-to-severe plaque psoriasis. XOMA also has a future royalty interest in additional therapeutic antibody product candidates being developed by others as a result of licensing its technologies. XOMA's pipeline includes both products and collaborative programs at various stages of preclinical and clinical development primarily directed toward treatments for cancer and immune disorders. In addition to supporting its product pipeline, the Company uses its infrastructure to provide process development and manufacturing services on a fee-for-service basis.

RAPTIVA (Efalizumab)

The Company markets RAPTIVA under an agreement with Genentech, Inc. as a result of a prior collaborative product development program. RAPTIVA is a humanized therapeutic monoclonal antibody developed to treat immune system disorders. RAPTIVA can be self-administered by patients as a single, once-weekly subcutaneous injection. In 2005, Serono had launched RAPTIVA in over 40 countries worldwide.

RAPTIVA competes with Enbrel from Amgen Inc. and its partner Wyeth Pharmaceuticals; Amevive from Biogen Idec Inc.; BG-12 from Biogen Idec Inc. and Fumapharm AG; Remicade from Centocor, Inc. Humira from Abbott Laboratories, and ISA247 from Isotechnika, Inc.

CHIR-12.12

CHIR-12.12, which is being developed by the Company in collaboration with Chiron Corporation, is an anti-CD40 antagonist antibody intended as a treatment for B-cell malignancies. In April 2005, XOMA announced the initiation of Phase I study for patients with advance chronic lymphocytic leukemia (CLL). Then in October 2005, the Company initiated a second Phase I study for patients with multiple myeloma (MM).

NEUPREX (opebacan/rBPI21)

NEUPREX (opebacan/rBPI21) is an injectable formulation of rBPI21, a modified recombinant fragment of human bactericidal/permeability-increasing protein (BPI). BPI is a human host-defense protein made by a type of white blood cell that is involved in the body's defenses against microbial infection. In October of 2003, in conjunction with Children's Medical Center Dallas, the Company announced the initiation of an open-label, single center, dose escalation, investigator-sponsored, Phase I/II clinical trial of NEUPREX in pediatric patients with congenital heart abnormalities requiring open heart surgery associated with cardiopulmonary bypass.

XMA005.2

XMA005.2 is a Human Engineered monoclonal antibody with a high-affinity and potent inhibitory activity against its inflammatory target. This high potency means that it may be suitable for use as a monthly-dose injectable therapeutic. XOMA is evaluating XMA005.2 in preclinical studies targeting multiple indications, including osteoarthritis and rheumatoid arthritis, where less frequent dosing could be a significant marketing advantage.

Anti-gastrin Mab

In September of 2004, XOMA announced a worldwide collaboration with Aphton Corporation to develop treatments for gastrointestinal (GI) and other gastrin-sensitive cancers using anti-gastrin monoclonal antibodies. Gastrin has been shown to be involved in the progression of colorectal, stomach, liver and pancreatic cancers and inhibiting gastrin may inhibit such growth.

Metabolic Disease Target

The Company is co-developing Metabolic Disease Target with Lexicon Genetics. Metabolic Disease Target is a secreted protein involved in metabolic functions such as insulin sensitivity and weight gain that was identified through Lexicon's Knockout Technology. Antibodies to this target may be developed to treat Type II diabetes, obesity and other metabolic diseases.

MLN2222

MLN2222 (also known as CAB2) is being developed by XOMA in partnership with Millennium Pharmaceuticals, Inc. MLN2222 is a complement inhibitor for coronary artery bypass graft surgery tar

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net